Where would you like to sign in?

First Metformin Gum Patent Granted to Generex Biotechnology

TORONTO -- (MARKET WIRE) -- November 14, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT),
the leader in drug delivery for metabolic diseases through the inner lining
of the mouth, announced today that it has been granted the first patent for
its medicinal gum platform titled "Compositions for Oral Transmucosal
Delivery of Metformin." The patent covers claims to the composition,
processes, and methodologies for the delivery of an oral transmucosal
metformin composition via the oral mucosal membrane for absorption.

This patent was issued by the Lebanese Ministry of National Economy
Intellectual Property Protection Office. As a consequence of Lebanon's
accession to the international Patent Co-operation Treaty, this patent will
open the door to further filings in the other PCT signatory countries.

Metformin is a generic drug used to regulate blood glucose (sugar) levels
by reducing the amount of glucose produced by the liver, and by making the
insulin produced by the body work more effectively to reduce the amount of
glucose already in the blood. Metformin has been in use around the world
for more than 30 years. It remains the most prescribed drug for Type-2
diabetes, a testimony to its efficacy and its prominent place in diabetes
therapy. The total US market sales of all forms of metformin are
approximately $1.8 Billion (IMS-MAT: December 2003).

The patent relates to an oral transmucosal metformin composition comprising
a pharmaceutically acceptable carrier being capable of delivering a
pharmaceutically effective amount of metformin to the oral mucosal membrane
for absorption.

"We are very pleased to receive the first patent for our metformin gum
product, a product that complements our flagship product, Generex
Oral-lyn™, and related diabetes pipeline," said Rose C. Perri, the
Generex Chief Operating Officer.

The Company currently holds an aggregate of 80 patents worldwide (20 of
which are United States Patents) and has an aggregate of 60 patent
applications pending in various jurisdictions.

About Generex

Generex is engaged in the research and development of drug delivery systems
and technologies. Generex has developed a proprietary platform technology
for the delivery of drugs into the human body through the oral cavity (with
no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the
body by the lining of the inner mouth using the Company's proprietary
RapidMist™ device. The Company's flagship product, oral insulin
(Generex Oral-lyn™), which is available for sale in Ecuador for the
treatment of patients with Type-1 and Type-2 diabetes, is in various stages
of clinical trials around the world. For more information, visit the
Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to
time by Generex representatives concerning the same subject matter may
contain "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements can be
identified by introductory words such as "expects," "plans," "intends,"
"believes," "will," "estimates," "forecasts," "projects" or words of
similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently are
used in discussing potential product applications, potential
collaborations, product development activities, clinical studies,
regulatory submissions and approvals, and similar operating matters. Many
factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known
risks and uncertainties include those identified from time to time in the
reports filed by Generex with the Securities and Exchange Commission,
which should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and
one should avoid placing undue reliance on such statements. Generex cannot
be sure when or if it will be permitted by regulatory agencies to undertake
additional clinical trials or to commence any particular phase of clinical
trials. Because of this, statements regarding the expected timing of
clinical trials cannot be regarded as actual predictions of when Generex
will obtain regulatory approval for any "phase" of clinical trials.
Generex claims the protection of the safe harbor for forward-looking
statements that is contained in the Private Securities Litigation Reform
Act.